Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA.
Sci Signal. 2017 Sep 12;10(496):eaam6291. doi: 10.1126/scisignal.aam6291.
mutant non-small cell lung cancer (NSCLC) may be classified into epithelial or mesenchymal subtypes. Despite having the same "driver" mutation, mesenchymal NSCLCs are less responsive than are epithelial NSCLCs to inhibition of the RAS pathway. Identifying alternative networks that promote survival specifically in mesenchymal NSCLC may lead to more effective treatments for this subtype. Through their numerous targets in cellular signaling pathways, noncoding microRNAs (miRNAs) often function as tumor suppressors or oncogenes. In particular, some miRNAs regulate the epithelial-mesenchymal transition (EMT). We derived an EMT-related miRNA signature by profiling the abundance of miRNAs in a panel of epithelial (KE) or mesenchymal (KM) mutant NSCLC cell lines. This signature revealed a number of suppressed miRNAs in KM cell lines, including members of the miR-200 family, which can suppress tumor progression by inhibiting EMT. Reconstituting KM cells with one of these miRNAs, miR-124, disrupted autophagy and decreased cell survival by reducing the abundance of p62, which is both an adaptor for selective autophagy and a regulator of the transcription factor nuclear factor κB (NF-κB). Suppression of p62 by miR-124 correlated with reduced abundance of the autophagy activator beclin 1 (BECN1), the ubiquitin ligase TRAF6, and the NF-κB subunit RELA/p65. The abundance of miR-124 inversely correlated with the expression of and in patient NSCLC samples. These findings reveal how the loss of miR-124 promotes cell survival networks in the aggressive mesenchymal subtype of mutant NSCLC, which might lead to improved subtype-selective therapeutic strategies for patients.
突变型非小细胞肺癌 (NSCLC) 可分为上皮型或间质型亚型。尽管具有相同的“驱动”突变,但间质型 NSCLC 对 RAS 通路抑制的反应性低于上皮型 NSCLC。确定促进间质型 NSCLC 存活的替代网络可能会为这种亚型带来更有效的治疗方法。通过其在细胞信号通路中的众多靶标,非编码 microRNA (miRNA) 通常作为肿瘤抑制因子或癌基因发挥作用。特别是,一些 miRNA 调节上皮-间质转化 (EMT)。我们通过对一组上皮型 (KE) 或间质型 (KM) 突变型 NSCLC 细胞系中 miRNA 的丰度进行分析,得出了一个与 EMT 相关的 miRNA 特征。该特征揭示了 KM 细胞系中许多受抑制的 miRNA,包括 miR-200 家族的成员,其通过抑制 EMT 抑制肿瘤进展。用其中一种 miRNA(miR-124)重建 KM 细胞,通过降低自噬调节剂 p62 的丰度破坏自噬并降低细胞存活率,p62 既是选择性自噬的接头,也是转录因子核因子 κB (NF-κB) 的调节剂。miR-124 对 p62 的抑制与自噬激活剂 beclin 1 (BECN1)、泛素连接酶 TRAF6 和 NF-κB 亚基 RELA/p65 的丰度降低相关。miR-124 的丰度与患者 NSCLC 样本中 和 的表达呈负相关。这些发现揭示了 miR-124 的缺失如何促进突变型 NSCLC 侵袭性间质型的细胞存活网络,这可能会为患者带来改善的亚型选择性治疗策略。